- Home
- IGC vs PLUR Comparison
IGC vs PLUR Comparison
Compare IGC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- PLUR
- Stock Information
- Founded
- IGC 2005
- PLUR 2001
- Country
- IGC United States
- PLUR Israel
- Employees
- IGC N/A
- PLUR N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IGC Health Care
- PLUR Health Care
- Exchange
- IGC Nasdaq
- PLUR Nasdaq
- Market Cap
- IGC 39.8M
- PLUR 36.9M
- IPO Year
- IGC N/A
- PLUR N/A
- Fundamental
- Price
- IGC $0.40
- PLUR $3.91
- Analyst Decision
- IGC Strong Buy
- PLUR Strong Buy
- Analyst Count
- IGC 2
- PLUR 1
- Target Price
- IGC $4.00
- PLUR $12.00
- AVG Volume (30 Days)
- IGC 886.9K
- PLUR 10.5K
- Earning Date
- IGC 11-14-2025
- PLUR 11-11-2025
- Dividend Yield
- IGC N/A
- PLUR N/A
- EPS Growth
- IGC N/A
- PLUR N/A
- EPS
- IGC N/A
- PLUR N/A
- Revenue
- IGC $1,327,000.00
- PLUR $1,336,000.00
- Revenue This Year
- IGC $3.54
- PLUR $97.38
- Revenue Next Year
- IGC $15.12
- PLUR $293.97
- P/E Ratio
- IGC N/A
- PLUR N/A
- Revenue Growth
- IGC 24.95
- PLUR 309.82
- 52 Week Low
- IGC $0.25
- PLUR $3.33
- 52 Week High
- IGC $0.50
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- IGC 46.88
- PLUR 41.69
- Support Level
- IGC $0.36
- PLUR $3.60
- Resistance Level
- IGC $0.43
- PLUR $4.09
- Average True Range (ATR)
- IGC 0.02
- PLUR 0.18
- MACD
- IGC 0.00
- PLUR -0.02
- Stochastic Oscillator
- IGC 46.64
- PLUR 30.69
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.